US Patent

US11969409 — Formulations of apremilast

Formulation · Assigned to Amgen Inc · Expires 2042-05-27 · 16y remaining

Vulnerability score 38/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects formulations of apremilast, specifically oral dosage forms that provide once-a-day dosing of the drug.

USPTO Abstract

Provided herein are oral dosage forms comprising a) a core tablet comprising (i) a drug layer comprising apremilast and hypromellose acetate succinate (HPMCAS) in an amorphous solid dispersion; and (ii) a swellable layer comprising one or more swellable polymers; and b) a coating layer disposed on the core tablet, wherein the oral dosage form surface comprises at least one drug release orifice. The disclosed oral dosage forms provide once-a-day dosing of apremilast and are suitable for treating diseases or disorders ameliorated by inhibiting phosphodiesterase subtype IV (PDE4).

Drugs covered by this patent

Patent Metadata

Patent number
US11969409
Jurisdiction
US
Classification
Formulation
Expires
2042-05-27
Drug substance claim
No
Drug product claim
Yes
Assignee
Amgen Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.